ATEC vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals significant concerns with a Piotroski F-Score of 4/9, indicating borderline financial health, and the absence of an Altman Z-Score prevents a full solvency assessment. Despite strong revenue growth of 30.4% and a bullish analyst recommendation (strong_buy), the company is unprofitable with a -21.29% profit margin and an alarming ROE of -540.41%. High valuation multiples, including a Price/Book of 200.26 and Forward P/E of 79.16, are not supported by current earnings or cash flow, while insider selling of $55.28M in the last six months signals strong bearish sentiment from management. Technical trend is bearish, and recent price performance shows a sharp 1-month decline of -24.8%, suggesting weakening momentum.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ATEC vs LLY: Head-to-Head Comparison
This page compares Alphatec Holdings, Inc. (ATEC) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.